（单词翻译:单击）
Chinese drug maker1 Aosaikang Pharmaceutical2 became the first company to postpone3 its initial public offering after China reopened its IPO market. The China Securities Regulatory Commission has allegedly halted the proposed listing after Aosaikang priced its stock at 72 yuan 99 cents.
The price is 67 times Aosaikang's earnings4 and is a much higher ratio than the company's comparable peers. Aosaikang had aimed to raise 4 billion yuan, or just over 660 million US dollars by listing on the Shenzhen Stock Exchange.
It intended to use most of the proceeds to buy shares of its parent Nanjing Aosaikang Pharmaceutical.
